CNS Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

De CEO CNS Pharmaceuticals is John Climaco, benoemd in Sep2017, heeft een ambtstermijn van 7.17 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 525.00K, bestaande uit 100% salaris en 0% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.024% van de aandelen van het bedrijf, ter waarde $ 1.48K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.4 jaar en 1.9 jaar.

Belangrijke informatie

John Climaco

Algemeen directeur

US$525.0k

Totale compensatie

Percentage CEO-salaris	100.0%
Dienstverband CEO	7.2yrs
Eigendom CEO	0.02%
Management gemiddelde ambtstermijn	5.4yrs
Gemiddelde ambtstermijn bestuur	1.9yrs

Recente managementupdates

Recent updates

CNS Pharmaceuticals reports Q2 results

Aug 15

Here's Why We're A Bit Worried About CNS Pharmaceuticals' (NASDAQ:CNSP) Cash Burn Situation

Dec 04

CNS Pharmaceuticals sinks after pricing equity offering of $10M

Dec 23

Analyse CEO-vergoeding

Hoe is John Climaco's beloning veranderd ten opzichte van CNS Pharmaceuticals's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$17m
Jun 30 2024	n/a	n/a	-US$16m
Mar 31 2024	n/a	n/a	-US$17m
Dec 31 2023	US$525k	US$525k	-US$19m
Sep 30 2023	n/a	n/a	-US$19m
Jun 30 2023	n/a	n/a	-US$18m
Mar 31 2023	n/a	n/a	-US$17m
Dec 31 2022	US$828k	US$525k	-US$15m
Sep 30 2022	n/a	n/a	-US$13m
Jun 30 2022	n/a	n/a	-US$14m
Mar 31 2022	n/a	n/a	-US$14m
Dec 31 2021	US$846k	US$525k	-US$14m
Sep 30 2021	n/a	n/a	-US$14m
Jun 30 2021	n/a	n/a	-US$12m
Mar 31 2021	n/a	n/a	-US$11m
Dec 31 2020	US$2m	US$440k	-US$9m
Sep 30 2020	n/a	n/a	-US$9m
Jun 30 2020	n/a	n/a	-US$8m
Mar 31 2020	n/a	n/a	-US$6m
Dec 31 2019	US$1m	US$214k	-US$4m
Sep 30 2019	n/a	n/a	-US$8m
Jun 30 2019	n/a	n/a	-US$7m
Mar 31 2019	n/a	n/a	-US$7m
Dec 31 2018	US$164k	US$150k	-US$7m
Dec 31 2017	US$140k	US$50k	-US$526k

Compensatie versus markt: De totale vergoeding ($USD 525.00K ) John } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 649.63K ).

Compensatie versus inkomsten: De vergoeding van John is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

John Climaco (55 yo)

7.2yrs

Tenure

US$525,000

Compensatie

Mr. John Michael Climaco, Esq., J.D served as Chairman of the Board at CNS Pharmaceuticals, Inc. and joined CNS in September 2017. Mr. Climaco has been the Chief Executive Officer of CNS Pharmaceuticals, I...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
John Climaco	CEO, President & Director	7.2yrs	US$525.00k	0.024% $ 1.5k
Christopher Downs	Chief Financial Officer	5yrs	US$401.52k	0.011% $ 649.4
Sandra Silberman	Chief Medical Officer	no data	US$270.15k	0.00052% $ 32.1
Waldemar Priebe	Founder	no data	geen gegevens	geen gegevens
Donald Picker	Chief Science Officer	5.4yrs	geen gegevens	geen gegevens

5.4yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van CNSP is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.4 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
John Climaco	CEO, President & Director	no data	US$525.00k	0.024% $ 1.5k
Faith Charles	Independent Chairman of Board	1.9yrs	US$112.64k	0.0013% $ 77.7
Jeffry Keyes	Independent Director	6.4yrs	US$135.46k	0.0020% $ 121.5
Bettina Cockroft	Independent Director	1.5yrs	US$58.31k	0.00064% $ 39.5
Jerzy Gumulka	Independent Director	7yrs	US$115.16k	0.0064% $ 393.5
Sigmund Hsu	Scientific Advisory Board Member	no data	geen gegevens	geen gegevens
Amy Mahery	Independent Director	less than a year	geen gegevens	0.00022% $ 13.6

1.9yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van CNSP wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.9 jaar), wat duidt op een nieuw bestuur.

CNS Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

CNS Pharmaceuticals, Inc., Annual General Meeting, Apr 30, 2024

CNS Pharmaceuticals, Inc. Appoints Amy Mahery to its Board of Directors

CNS Pharmaceuticals, Inc., Annual General Meeting, Sep 14, 2023

CNS Pharmaceuticals, Inc., Annual General Meeting, Sep 14, 2023

Bettina M. Cockroft Joins CNS Pharmaceuticals, Inc.'s Board of Directors

Cns Pharmaceuticals, Inc. Appoints Faith Charles as Independent Member and as Chairperson of the Board of Directors

Recent updates

CNS Pharmaceuticals Receives Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $3 million.

CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement

CNS Pharmaceuticals, Inc. announced that it expects to receive funding from Cortice Biosciences Incorporated

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $5.2 million.

The Nasdaq Hearings Panel Grants the Requested Extension to CNS Pharmaceuticals Until August 12, 2024

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.98075 million.

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.98075 million.

CNS Pharmaceuticals, Inc. announced a financing transaction

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.3725 million.

New major risk - Share price stability

CNS Pharmaceuticals, Inc., Annual General Meeting, Apr 30, 2024

CNS Pharmaceuticals Receives Non-Compliance Letter Form Nasdaq

CNS Pharmaceuticals Provides Non-Compliance Update

CNS Pharmaceuticals, Inc. Appoints Amy Mahery to its Board of Directors

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

CNS Pharmaceuticals, Inc. Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy

New major risk - Negative shareholders equity

CNS Pharmaceuticals, Inc. Opens 46 Clinical Trial Sites Across the U.S., Italy, France, Spain, and Switzerland

Cns Pharmaceuticals, Inc. Announces Enrollment of 200 Patients in Ongoing Potentially Pivotal Study of Berubicin with the Treatment of Glioblastoma Multiforme (Gbm)

CNS Pharmaceuticals Receives Letter from Nasdaq Regarding Non-Compliance with Minimum of $2.5 Million in Stockholders’ Equity Requirement Pursuant to Nasdaq’s Listing Rule 5550(b)(1)

CNS Pharmaceuticals, Inc., Annual General Meeting, Sep 14, 2023

CNS Pharmaceuticals, Inc., Annual General Meeting, Sep 14, 2023

CNS Pharmaceuticals, Inc. Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme

Bettina M. Cockroft Joins CNS Pharmaceuticals, Inc.'s Board of Directors

CNS Pharmaceuticals Announces First Patient Enrolled in Spain in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

CNS Pharmaceuticals, Inc. Announces Investigator-Initiated Phase 1B/2 Trial to Be Conducted At the Pomeranian Medical University in Poland

Cns Pharmaceuticals, Inc. Appoints Faith Charles as Independent Member and as Chairperson of the Board of Directors

CNS Pharmaceuticals, Inc Announces Preliminary Results from Ongoing Potentially Pivotal Trial Evaluating Berubicin for the Treatment of Recurrent Glioblastoma Multiforme (GBM)

CNS Pharmaceuticals, Inc. has completed a Follow-on Equity Offering.

Insufficient new directors

CNS Pharmaceuticals, Inc. Announces Dosing of First Patient in Europe/France in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

CNS Pharmaceuticals, Inc. Announces Activation of First Clinical Trial Sites in Europe for Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

CNS Pharmaceuticals, Inc. Provides A Clinical Update of Its Anti-Cancer Drug Candidates Currently in Development for the Treatment of Primary and Metastatic Brain and CNS Cancer

CNS Pharmaceuticals reports Q2 results

CNS Pharmaceuticals, Inc., Annual General Meeting, Jul 27, 2022

CNS Pharmaceuticals Inc. Receives Approval from U.S. FDA for Protocol Amendment to Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

CNS Pharmaceuticals, Inc. Announces Presentation of Ongoing Potentially Pivotal Berubicin Clinical Trial Design at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

Price target increased to US$10.00

Insufficient new directors

CNS Pharmaceuticals, Inc. Receives Approval from Competent Authority of Switzerland for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme

CNS Pharmaceuticals, Inc. announced that it expects to receive $11.500001 million in funding

Insufficient new directors

Here's Why We're A Bit Worried About CNS Pharmaceuticals' (NASDAQ:CNSP) Cash Burn Situation

CNS Pharmaceuticals, Inc. Receives Approval from Switzerland Ethics Committee for its Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme

FDA Grants Fast Track Designation to CNS Pharmaceuticals, Inc. for Berubicin for the Treatment of Recurrent Glioblastoma Multiforme

CNS Pharmaceuticals Commences Patient Enrollment in Potentially Pivotal Study of Berubicin

CNS Pharmaceuticals Berubicin Trial is on Schedule to Commence in March 2021

WPD Pharmaceuticals and CNS Pharmaceuticals, Inc. Announces Berubicin Supply Agreement for the Upcoming Clinical Trials

WPD Pharmaceuticals and CNS Pharmaceuticals, Inc. Announce Positive Opinion of the Polish Central Ethics Committee for the WPD-201 Study and Central IRB Study Level Approval for the CNS-201 Study

New 90-day high: US$3.50

CNS Pharmaceuticals Announces It Has Been Featured in Syndicated Broadcast Covering Recent FDA Approval of IND Application

CNS Pharmaceuticals sinks after pricing equity offering of $10M

CNS Pharmaceuticals, Inc. Announces FDA Approval of IND Application for its Brain Cancer Drug Candidate Berubicin

New 90-day high: US$2.89

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd